Sector News

Abbott snaps up Glomed for undisclosed price

September 7, 2016
Life sciences

Abbott picked up Vietnamese drug manufacturer Glomed for an undisclosed price in a deal that gives the pharma giant two manufacturing facilities in that country in addition to expanding its visibility in Southeast Asia.

U.S.-based Abbott, which has a 20-year presence in Vietnam, is known in the region for its formula milk. With the Glomed transaction, Abbott picks up two manufacturing plants in Vietnam’s Binh Duong province, 5 branches and more than 800 employees.

Abbott said it intends to focus on anti-infectives, gastroenterology, pain management, cardiovascular, respiratory and women’s health, and over-the-counter products.

The company is already known in the area for nutrition and its portfolio in medical devices and diagnostics.

“The company intends to build on Glomed’s success to date to ensure long-term growth in the country,” Ngo Van Huy, general manager of Abbott Vietnam’s pharmaceuticals business, told VN Express, adding that the deal will enhance Abbott’s ability to serve patients in Vietnam with innovative, high-quality healthcare solutions.

Vietnam has been opening its doors to more foreign investment over a number of industries in the wake of new policies such as the signing of the Trans-Pacific Partnership trade pact.

In July, Tokyo-based Taisho Pharmaceutical bought a 24.5% stake in Vietnam’s DHG Pharmaceutical, the country’s top drug distributor that handles a wide variety of prescription therapies, over-the-counter treatments and personal care products.

By Joseph Keenan

Source: Fierce Pharma

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach